Bank of New York Mellon Corp Has $1.51 Million Holdings in OPKO Health, Inc. (NASDAQ:OPK)

Bank of New York Mellon Corp lessened its position in shares of OPKO Health, Inc. (NASDAQ:OPK) by 3.7% in the fourth quarter, HoldingsChannel.com reports. The firm owned 1,024,907 shares of the biotechnology company’s stock after selling 39,372 shares during the quarter. Bank of New York Mellon Corp’s holdings in OPKO Health were worth $1,507,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the company. Rubric Capital Management LP increased its position in OPKO Health by 9.6% during the 3rd quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company’s stock valued at $72,573,000 after purchasing an additional 4,284,336 shares during the period. PFG Investments LLC grew its position in shares of OPKO Health by 9.4% during the 4th quarter. PFG Investments LLC now owns 1,160,885 shares of the biotechnology company’s stock worth $1,707,000 after buying an additional 99,795 shares during the period. Clearline Capital LP acquired a new stake in shares of OPKO Health during the 3rd quarter worth approximately $1,083,000. Barclays PLC grew its position in shares of OPKO Health by 154.5% during the 3rd quarter. Barclays PLC now owns 543,336 shares of the biotechnology company’s stock worth $810,000 after buying an additional 329,870 shares during the period. Finally, BNP Paribas Financial Markets grew its position in shares of OPKO Health by 736.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 246,967 shares of the biotechnology company’s stock worth $368,000 after buying an additional 217,450 shares during the period. Institutional investors and hedge funds own 64.63% of the company’s stock.

OPKO Health Price Performance

Shares of OPK opened at $1.80 on Friday. OPKO Health, Inc. has a 12-month low of $0.92 and a 12-month high of $2.04. The business’s fifty day moving average is $1.65 and its 200 day moving average is $1.57. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30. The stock has a market cap of $1.21 billion, a P/E ratio of -9.47 and a beta of 1.70.

OPKO Health (NASDAQ:OPK) last issued its earnings results on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.09. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. The company had revenue of $183.60 million for the quarter, compared to analysts’ expectations of $155.42 million. Sell-side analysts anticipate that OPKO Health, Inc. will post -0.25 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Phillip Md Et Al Frost acquired 150,000 shares of the company’s stock in a transaction on Friday, January 17th. The shares were acquired at an average cost of $1.47 per share, for a total transaction of $220,500.00. Following the purchase, the chief executive officer now owns 213,186,477 shares in the company, valued at approximately $313,384,121.19. The trade was a 0.07 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders have bought a total of 964,971 shares of company stock worth $1,493,692 in the last ninety days. Corporate insiders own 47.26% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and set a $3.00 price objective on shares of OPKO Health in a research report on Wednesday. Barrington Research reaffirmed an “outperform” rating and set a $2.25 price objective on shares of OPKO Health in a research report on Wednesday, March 12th. Finally, StockNews.com raised shares of OPKO Health from a “sell” rating to a “hold” rating in a research report on Monday, March 3rd.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.